Anzeige
Mehr »
Login
Montag, 04.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Sagenhafte +10.000 % Gewinnchance mit Spezialisten für KI-Cybersecurity!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 864341 | ISIN: JP3784600003 | Ticker-Symbol: HPX
Frankfurt
04.11.24
08:14 Uhr
26,600 Euro
+0,200
+0,76 %
Branche
Pharma
Aktienmarkt
JAPAN
1-Jahres-Chart
HISAMITSU PHARMACEUTICAL CO INC Chart 1 Jahr
5-Tage-Chart
HISAMITSU PHARMACEUTICAL CO INC 5-Tage-Chart
RealtimeGeldBriefZeit
26,60027,80019:52
ACCESSWIRE
404 Leser
Artikel bewerten:
(2)

Hisamitsu America Marks 90 Years of Pioneering Pain Relief with Salonpas with Record Sales

FLORHAM PARK, NJ / ACCESSWIRE / March 1, 2024 / Hisamitsu America, today, celebrates the 90th anniversary of the Salonpas® patch, the world's No. 1 brand of Over-the-Counter (OTC) topical analgesics in the patch category,1 which was introduced in Japan in 1934.

Hisamitsu Pharmaceutical Co. Inc., with dual headquarters in Kyushu and Tokyo is the parent company of Hisamitsu America, manufacturer of Salonpas® and global pioneer and innovator of transdermal and topical patch technology operating around the world.

"Since its inception, the Salonpas brand has evolved into a legacy of trusted and effective OTC pain relief solutions including patches, creams, gels, sprays and liquids," says John Incledon, President & CEO, Hisamitsu America, the marketers of Salonpas, the #1 Doctor and Pharmacist recommended OTC Topical Pain Patch2 and the first FDA-approved OTC topical pain reliever in 2008 with the Salonpas® Pain Relief Patch.

Time-Tested, Research-Driven, Cross-Generational Efficacy

"Salonpas is more than a pain relief patch; it's a symbol of time-tested, trusted medicine that transcends generations," said Bob Arnot, M.D., internal medicine who is a journalist, author and served as a medical and foreign correspondent for NBC and CBS. "Crafted with care and precision, Salonpas has become synonymous with effective and innovative OTC topical pain relief solutions."

Remarkable Growth in the U.S. Market

Since 2010, Salonpas® has witnessed extraordinary growth in the U.S. market. Retail sales have surged over tenfold, reaching over $200 million3 in 2023. "This achievement underscores the brand's ongoing commitment in bringing innovation to the topical pain relief category to satisfy a growing number of customers," says Incledon.

Despite Salonpas achieving record revenues in the U.S., less than 1 in 3 U.S. households are buying products in the External Analgesics category, with the Salonpas OTC brand facing even lower consumer adoption.4

"I see Hisamitsu America as the 'little engine that could,' continually striving to win the hearts and minds of every pharmacist, doctor, and consumer," says Incledon. "People who have discovered Salonpas are satisfied and brand loyal, but our goal is to bring many more people under the 'topicals tent' like other parts of the world, especially Japan. People have many effective options for pain relief that do not involve taking a pill."

'Salonpas' is cited as the fastest growing search term - up 98.8% in 20235 with more Facebook fans and followers than any other systemic or topical OTC analgesic brand6. The brand continues to innovate and educate with the extraordinary growth of the Salonpas brand in the United States reinforced by the success of the Salonpas Lidocaine 4% Pain Relieving FLEX Patch distinguished as the #1 new item in the External Analgesics OTC category7.

"As we mark this significant milestone, we extend our gratitude to our loyal customers, partners, and dedicated teams worldwide. The 90th Anniversary of Salonpas is not just a celebration of the past but a reaffirmation of our commitment to advancing pain relief solutions for the future," says Incledon.

Since its formation, the company mission of Hisamitsu is to improve the quality of life for people around the world through R&D, manufacturing, and the sale of topical analgesic products. Hisamitsu's culture focuses on spreading compassionate consideration to others.

About Hisamitsu America:

Hisamitsu America is the North American subsidiary of Hisamitsu Pharmaceutical Co., Inc., founded in 1847, a global pioneer and innovator of transdermal and topical patch technology with a focus on pain relief. The Salonpas® product line, which gained early acceptance in Asia and is now registered in over 100 countries, has pioneered the development of topical patches to relieve pain. Since 2010, Salonpas has become one of the fastest growing OTC brands in the USA. Salonpas became the most popular pain relief brand on Facebook in 2020. For more information, visit: https://us.hisamitsu/.

Sources:

  1. Salonpas® Named the World's No. 1 OTC Topical Analgesic Patch Brand - Euromonitor International Limited (global topical analgesics/anaesthetic market, 2022 data.)
  2. Salonpas is the #1 Doctor and Pharmacist recommended OTC Topical Pain Patch Brand (IQVIA: ProVoice Survey 2023)
  3. Salonpas retail sales exceeded $200 mm with record sales across Food, Drug, Mass, Club, and ecommerce channels (Circana: MULO/Club & Ecommerce data ending 12/31/23).
  4. Less than 1 in 3 households buy products in the general category of External Analgesics in U.S. households, with the Salonpas OTC brand attracting 1 in 20 households. (Circana HH Panel, Rolling 52 weeks data ending 12/31/23)
  5. 'Salonpas' has been cited as the fastest growing search term - up 98.8% in 2023 (CommerceIQ, 2023)
  6. More Facebook fans and followers than any other systemic or topical OTC analgesic brand. (Meta: March 2024)
  7. Salonpas Lidocaine 4% Pain Relieving FLEX Patch is distinguished as the #1 new item in the External Analgesics OTC category (Circana MULO, 52 wks. ending 12/31/23)

Media Contact: Nancy Thompson, Vorticom, Inc. 212.532.2208 (o), 917.371.4053 (m); nancyt@vorticom.com

SOURCE: Hisamitsu America



View the original press release on accesswire.com

© 2024 ACCESSWIRE
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.